TORONTO, ONTARIO — (November 25, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company’s pipeline, as described in the CEO Letter of April 2014. These studies have demonstrated that ATB-352 potently inhibits the production of pain-signalling chemicals (prostaglandins) in rats, but does not produce significant ulceration in the stomach or intestine, even at very high doses. In the same study, administration of the painkiller ketoprofen caused severe and extensive intestinal ulceration and bleeding.
“ATB-352 has a novel mechanism of action”, said Antibe’s Chief Science Officer, Dr. John Wallace. “The small amounts of hydrogen sulfide that are released from this drug exert a potent protective effect in the stomach and intestine. This drug was designed to address a substantial unmet medical need, and a market exceeding $2 billion annually”.
ATB-352 is a potent pain-killer intended for use in the short-term treatment of conditions characterized by severe pain, including that associated with herniated discs, gout, ankylosing spondylitis, migraines, traumatic injuries, muscle aches, post-surgical pain, toothache and menstrual cramps. Dan Legault, Antibe’s CEO remarked, “For many patients, there are only two viable options for treatment of severe pain: traditional non-steroidal anti-inflammatory drugs (NSAIDs), which can cause severe gastrointestinal bleeding, and opiates, which carry the risks of addiction and abuse. ATB-352 is intended to provide an important third option to this large group of patients.”
About Antibe Therapeutics Inc.Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking InformationThis news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact InformationAntibe Therapeutics Inc.
Chief Executive Officer
Tel: +1 416-473-4095